121 related articles for article (PubMed ID: 26576494)
1. Gaining power and precision by using model-based weights in the analysis of late stage cancer trials with substantial treatment switching.
Bowden J; Seaman S; Huang X; White IR
Stat Med; 2016 Apr; 35(9):1423-40. PubMed ID: 26576494
[TBL] [Abstract][Full Text] [Related]
2. A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.
Royston P; B Parmar MK
Trials; 2020 Apr; 21(1):315. PubMed ID: 32252820
[TBL] [Abstract][Full Text] [Related]
3. Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.
Latimer NR; Abrams KR; Lambert PC; Morden JP; Crowther MJ
Stat Methods Med Res; 2018 Mar; 27(3):765-784. PubMed ID: 27114326
[TBL] [Abstract][Full Text] [Related]
4. rpsftm: An R Package for Rank Preserving Structural Failure Time Models.
Allison A; White IR; Bond S
R J; 2017 Dec; 9(2):342-353. PubMed ID: 29564164
[TBL] [Abstract][Full Text] [Related]
5. An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect.
Royston P; Parmar MK
Trials; 2014 Aug; 15():314. PubMed ID: 25098243
[TBL] [Abstract][Full Text] [Related]
6. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
Latimer NR; White IR; Abrams KR; Siebert U
Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
[TBL] [Abstract][Full Text] [Related]
7. A causal proportional hazards estimator for the effect of treatment actually received in a randomized trial with all-or-nothing compliance.
Loeys T; Goetghebeur E
Biometrics; 2003 Mar; 59(1):100-5. PubMed ID: 12762446
[TBL] [Abstract][Full Text] [Related]
8. Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.
Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
Med Decis Making; 2014 Apr; 34(3):387-402. PubMed ID: 24449433
[TBL] [Abstract][Full Text] [Related]
9. A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials.
Horiguchi M; Cronin AM; Takeuchi M; Uno H
Stat Med; 2018 Jul; 37(15):2307-2320. PubMed ID: 29682762
[TBL] [Abstract][Full Text] [Related]
10. Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study.
Morden JP; Lambert PC; Latimer N; Abrams KR; Wailoo AJ
BMC Med Res Methodol; 2011 Jan; 11():4. PubMed ID: 21223539
[TBL] [Abstract][Full Text] [Related]
11. Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method.
Latimer NR; Abrams KR; Lambert PC; Crowther MJ; Wailoo AJ; Morden JP; Akehurst RL; Campbell MJ
Stat Methods Med Res; 2017 Apr; 26(2):724-751. PubMed ID: 25416688
[TBL] [Abstract][Full Text] [Related]
12. Weighted logrank tests for interval censored data when assessment times depend on treatment.
Fay MP; Shih JH
Stat Med; 2012 Dec; 31(28):3760-72. PubMed ID: 22786795
[TBL] [Abstract][Full Text] [Related]
13. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
[TBL] [Abstract][Full Text] [Related]
14. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer NR; Abrams KR; Siebert U
BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
[TBL] [Abstract][Full Text] [Related]
15. Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size.
Xu R; Mehrotra DV; Shaw PA
Pharm Stat; 2019 May; 18(3):366-376. PubMed ID: 30706642
[TBL] [Abstract][Full Text] [Related]
16. Delayed treatment effects, treatment switching and heterogeneous patient populations: How to design and analyze RCTs in oncology.
Ristl R; Ballarini NM; Götte H; Schüler A; Posch M; König F
Pharm Stat; 2021 Jan; 20(1):129-145. PubMed ID: 32830428
[TBL] [Abstract][Full Text] [Related]
17. A Validation Study of the Rank-Preserving Structural Failure Time Model: Confidence Intervals and Unique, Multiple, and Erroneous Solutions.
Ouwens M; Hauch O; Franzén S
Med Decis Making; 2018 May; 38(4):509-519. PubMed ID: 29607730
[TBL] [Abstract][Full Text] [Related]
18. Performance of statistical methods for analysing survival data in the presence of non-random compliance.
Odondi L; McNamee R
Stat Med; 2010 Dec; 29(29):2994-3003. PubMed ID: 20963732
[TBL] [Abstract][Full Text] [Related]
19. Introducing a new estimator and test for the weighted all-cause hazard ratio.
Ozga AK; Rauch G
BMC Med Res Methodol; 2019 Jun; 19(1):118. PubMed ID: 31185922
[TBL] [Abstract][Full Text] [Related]
20. Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.
Wang Y; Berlin JA; Pinheiro J; Wilcox MA
Clin Trials; 2015 Jun; 12(3):265-75. PubMed ID: 25733675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
